Nuvectis Pharma, Inc. (NVCT) NASDAQ
12.45
+0.41(+3.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.45
+0.41(+3.41%)
Currency In USD
Address
1 Bridge Plaza
Fort Lee, NJ 07024
United States of America (the)
Phone
201 614 3150
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
February 04, 2022
| Name | Title | Pay | Year Born |
| Ron Bentsur | Co-Founder, Chairman, Chief Executive Officer & President | 1.19M | 1966 |
| Enrique Poradosu | Co-Founder, Executive Vice President, Chief Scientific & Business Officer | 749,241 | 1967 |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer | 749,241 | 1984 |
| Michael Carson | Vice President of Finance | 0 | 1976 |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.